XORTX to Present at BIO International Convention 2022
June 13 2022 - 8:54AM
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX |
TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical
company focused on developing innovative therapies to treat
progressive kidney disease, is pleased to announce its
participation in the
BIO International
Convention 2022, being held June 13th through 16th, 2022. Dr. Allen
Davidoff, XORTX’s CEO, will present an overview on the Company,
including the Company’s progress to date and planned future
regulatory and clinical activities.
Dr. Allen Davidoff,
CEO of XORTX stated, “We are pleased that XORTX has been accepted
to present at the BIO International Convention 2022. This
presentation and accompanying meetings represent an opportunity to
continue outreach to pharmaceutical partners, licencing contacts
and industry partners. XORTX looks forward to a busy, productive
week with more than 30 scheduled meetings.”
The three-day biotechnology and pharmaceutical
science conference will be held at the San Diego, Convention
Center. The presentation by CEO of XORTX, Dr. Allen Davidoff will
take place, on Monday, June 13th at 2 pm Theater 1. The
presentation will not be available by webcast.
Pharmaceutical or
biotechnology partners can schedule one-on-one meetings with Dr.
Allen Davidoff and Mr. Amar Keshri, by registering with BIO
International and then proceeding through to the BIO
International 2022 1-on-1 meeting
platform.
XORTX continues to
build a strong, experienced, capable research and development team
to conduct our upcoming registration trial, including the
transition of Dr. David MacDonald from Chief Technology Officer to
consultant focused on regulatory and clinical operations for the
Company.
About XORTX Therapeutics
Inc.
XORTX is a pharmaceutical company with two
clinically advanced products in development – XRx-008 for Autosomal
Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute
kidney and other acute organ injury associated with Coronavirus /
COVID-19 infection and XRx-225 is a pre-clinical stage program for
Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its
clinical development stage products that target aberrant purine
metabolism and xanthine oxidase to decrease or inhibit production
of uric acid. At XORTX, we are dedicated to developing medications
to improve the quality of life and future health of patients.
Additional information on XORTX is available at www.xortx.com.
For further
information, please contact: |
|
|
|
Allen Davidoff, CEO |
Nick Rigopulos, Director of Communications |
adavidoff@xortx.com or +1 403 455 7727 |
nick@alpineequityadv.com or +1 617 901 0785 |
The TSX Venture Exchange and Nasdaq have neither approved nor
disapproved the contents of this news release. No stock exchange,
securities commission or other regulatory authority has approved or
disapproved the information contained herein.
Forward Looking Statements
This press release may contain express or
implied forward-looking statements pursuant to Canadian and U.S.
Federal securities laws. These forward-looking statements and their
implications are based on the current reasonable expectations of
the management of XORTX only, and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in such forward-looking statements.
Except as otherwise required by law, XORTX undertakes no obligation
to publicly release any revisions or updates to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. More detailed information about the risks and uncertainties
affecting XORTX is contained in the Company’s most recently filed
Annual Information Form and the Management Discussion and Analysis
for its most recent financial reporting period filed on the
Company’s SEDAR profile (www.sedar.com) and under the heading “Risk
Factors” in XORTX’s Registration Statement on Form F-1 filed with
the Securities and Exchange Commission (“SEC”) available on the
SEC's website, www.sec.gov.
XORTX Therapeutics (NASDAQ:XRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
XORTX Therapeutics (NASDAQ:XRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024